Stockscreener 앱 받기
36.90
0.65%
0.24
시간 외 거래:
36.90
전일 마감가:
$36.66
열려 있는:
$36.75
하루 거래량:
3.53M
Relative Volume:
1.03
시가총액:
$15.95B
수익:
$2.31B
순이익/손실:
$1.66B
주가수익비율:
16.04
EPS:
2.3
순현금흐름:
$827.02M
1주 성능:
+3.59%
1개월 성능:
-2.59%
6개월 성능:
+10.74%
1년 성능:
+26.07%
1일 변동 폭
$36.39
$36.96
1주일 범위
$35.52
$36.96
52주 변동 폭
$24.05
$38.00
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.90 | 15.64B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma PLC $RPRX Stock Position Increased by OMERS ADMINISTRATION Corp - MarketBeat
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - The Manila Times
Leading Biopharma Royalty Investor Royalty Pharma to Join Morgan Stanley Healthcare Conference Sept 9 - Stock Titan
Royalty Pharma PLC $RPRX Position Boosted by American Century Companies Inc. - MarketBeat
Magnetar Financial LLC Buys Shares of 161,496 Royalty Pharma PLC $RPRX - MarketBeat
Adage Capital Partners GP L.L.C. Sells 10,718,321 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What does recent volatility data suggest for Royalty Pharma plc2025 Geopolitical Influence & Community Verified Trade Signals - Newser
Royalty Pharma plc stock outlook for YEARDollar Strength & Low Drawdown Momentum Trade Ideas - Newser
Royalty Pharma plc stock prediction for this weekJuly 2025 Closing Moves & Free Safe Entry Trade Signal Reports - Newser
Royalty Pharma PLC $RPRX Shares Sold by Evergreen Capital Management LLC - MarketBeat
Is Royalty Pharma plc a candidate for recovery playJuly 2025 Trade Ideas & Smart Swing Trading Techniques - Newser
Short interest data insights for Royalty Pharma plcM&A Rumor & Low Risk Entry Point Tips - Newser
Walleye Capital LLC Has $354,000 Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma plc stock volume spike explainedQuarterly Profit Review & Verified Momentum Watchlists - Newser
What Fibonacci levels say about Royalty Pharma plc reboundPrice Action & Weekly Market Pulse Alerts - Newser
GMT Capital Corp Sells 890,200 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Using economic indicators to assess Royalty Pharma plc potentialJuly 2025 Update & AI Optimized Trading Strategy Guides - Newser
Royalty Pharma plc stock trendline breakdown2025 Biggest Moves & Trade Opportunity Analysis Reports - Newser
Will Royalty Pharma plc benefit from macro trendsJuly 2025 Outlook & Long-Term Safe Investment Ideas - Newser
Combining machine learning predictions for Royalty Pharma plcMarket Activity Summary & Daily Entry Point Trade Alerts - Newser
Will Royalty Pharma plc stock recover after recent drop2025 Volatility Report & Growth Focused Entry Point Reports - Newser
How to recover losses in Royalty Pharma plc stockDollar Strength & Weekly Setup with ROI Potential - Newser
Is Royalty Pharma plc currently under institutional pressure2025 Pullback Review & Long-Term Investment Growth Plans - khodrobank.com
Compound Planning Inc. Acquires New Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma plc stock forming a cup and handleJuly 2025 Action & Free High Accuracy Swing Entry Alerts - khodrobank.com
Is Royalty Pharma plc still worth holding after the dipQuarterly Performance Summary & Accurate Technical Buy Alerts - Newser
How to monitor Royalty Pharma plc with trend dashboardsQuarterly Earnings Report & Expert Curated Trade Ideas - Newser
Royalty Pharma PLC $RPRX Shares Sold by BNP Paribas Financial Markets - MarketBeat
Canada Pension Plan Investment Board Sells 151,617 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Applying sector rotation models to Royalty Pharma plcRecession Risk & Long-Term Capital Growth Strategies - Newser
Will Royalty Pharma plc benefit from AI trends2025 Volatility Report & Capital Protection Trading Alerts - khodrobank.com
Royalty Pharma prices $2 billion senior unsecured notes offering - StreetInsider
Ieq Capital LLC Has $2.19 Million Stake in Royalty Pharma PLC $RPRX - MarketBeat
Is a relief rally coming for Royalty Pharma plc holders2025 Market WrapUp & Safe Entry Point Identification - Newser
Royalty Pharma Prices $2 Billion Debt Offering - MarketScreener
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Royalty Pharma plc Announces Pricing of $2.0 Billion of Senior Unsecured Notes - MarketScreener
Is Royalty Pharma plc forming a reversal patternMarket Risk Summary & Weekly High Potential Stock Alerts - Newser
Technical signs of recovery in Royalty Pharma plc2025 Big Picture & Free Safe Capital Growth Stock Tips - Newser
How to interpret RSI for Royalty Pharma plc stockJuly 2025 Review & Fast Gaining Stock Reports - Newser
Royalty Pharma prices $2B senior unsecured notes - MSN
Applying Wyckoff theory to Royalty Pharma plc stockGlobal Markets & Real-Time Buy Zone Alerts - Newser
Will breakout in Royalty Pharma plc lead to full recovery2025 Analyst Calls & Fast Entry High Yield Stock Tips - Newser
Can Royalty Pharma plc expand its profit marginsJuly 2025 Final Week & Safe Capital Growth Trade Ideas - khodrobank.com
Royalty Pharma plc recovery potential after sell offEarnings Recap Report & Fast Gain Stock Trading Tips - Newser
Royalty Pharma Prices $2 Bln Offering Of Senior Unsecured Notes - Nasdaq
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes - The Manila Times
$2 Billion Debt Offering: Royalty Pharma Secures Major Financing Across Three Long-Term Tranches - Stock Titan
Royalty Pharma says it announces pricing of $2.0 billion of senior unsecured notes - MarketScreener
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes - GlobeNewswire Inc.
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
1.11%
자본화:
|
볼륨(24시간):